Skip to research
Margin Monkey THEMARGINMONKEY Start my free trialTry free

Natera (NTRA) stock in plain English

Free brief · no signupStart here
NTRAPublished Nov 15, 2026
Natera Inc
Healthcare · Diagnostics & Research
Sells circulating cell-free DNA blood tests that detect fetal genetic conditions and monitor tumor recurrence.
Assets:
Two core laboratoriesFacilities in California and Texas process millions of clinical diagnostic assays annually.
3,500 employeesA specialized scientific, genetic counseling, and clinical laboratory workforce.
3.6 million testsTotal annual diagnostic test volume run across cancer, prenatal, and organ health lines.
Locked assetIn the full report
Rated Nov 19, 2026

Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.

70
OPS ScoreOperating finances
Latest quote
+0.15%$289.92
$42.04B
n/a (loss)
$2.91B

Change shown by the quote provider. Data may be delayed.

Financial statements, in plain wordsSales, profit, debt and cash, year by year
Published Nov 15, 2026Quotes updated Nov 20, 04:00 UTCOPS Score, TMM Score and the rating are research summaries, not advice or forecasts.
That was NTRA. The desk has 1,900+ more companies.Each one comes with its scores, its flags and the sources behind them.
7 days free · No card

What does Natera (NTRA) do?

Natera Inc (NTRA) is a U.S.-listed company in Healthcare (Diagnostics & Research). What it does: Sells circulating cell-free DNA blood tests that detect fetal genetic conditions and monitor tumor recurrence. It analyzes microscopic fragments of DNA circulating in blood to detect fetal abnormalities and cancer recurrences. It is worth $42.04B on the market and sold $2.91B over the last year.

Market cap
$42.04B
P/E ratio
None (reported a loss)
Annual sales
$2.91B
Sector
Healthcare
Industry
Diagnostics & Research
Brief updated
Nov 15, 2026

Brands and businesses behind NTRA

  • Signatera: It detects residual cancer DNA from blood draws to help oncologists monitor tumor recurrence, earning diagnostic fee revenue.
  • Panorama: It screens maternal blood for fetal chromosomal abnormalities early in pregnancy, earning diagnostic fee revenue from patient testing.
  • Horizon: It tests carrier genetic mutations before pregnancy to identify risks of passing disorders to children, charging insurance providers.
  • Prospera: It checks blood samples from organ transplant recipients to detect early signs of rejection, earning clinical diagnostic reimbursements.
  • Anora: It analyzes miscarriage tissue to help determine the genetic causes of pregnancy loss, earning test reimbursement fees.

NTRA’s flags, in plain English

Each flag is a number from Natera’s reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 15, 2026.

Still Climbing

Sales up 42.6% a year over 5 years. Sales are higher than a year ago. Growth does not guarantee profit, so look at the margins too.

Stupid Cash

Can pay this year's bills 2.8 times over. Cash in the bank covers a long stretch of running costs. The company can fund itself without borrowing or selling new shares.

Low debt

Low debt, only 13% of shareholder equity. The company owes very little compared with what it earns, so a bad year is less likely to force its hand.

Burning Cash

Losing money, profit margin of -5.7%. The business spends more cash than it brings in. It has to cover the gap with cash on hand, new loans or new shares.

2 more green flags open with the free trial. Try it free for 7 days.

Questions about NTRA

How big is Natera?

Natera’s market cap is $42.04B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $2.91B: what customers paid the company over the last year, before any costs.

What is NTRA’s P/E ratio?

NTRA has no P/E ratio right now. The company reported a loss, so there is no yearly profit to price.

What could go wrong with NTRA?

Natera faces active patent infringement lawsuits and deceptive advertising disputes with competing diagnostic test providers. That is one risk on Natera’s card. Its first risk flag is Burning Cash, explained above. A flag reads what the company reported. It does not predict the price.

Where do these numbers come from?

From Natera’s own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. NTRA’s filings on SEC.gov. The Margin Monkey is research, not advice.

Your first 7 days are free.Search all 1,900+ companies and open every card. Members also get the ratings, Picks and the TMM Score.
7 days free · No card